{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:02:18Z","timestamp":1789502538138,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      This study investigates the eradication rate and adverse reaction rate of immune regulator spleen aminopeptide combined with standard quadruple therapy in treating\n                      <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                      (HP) infection and explores the mechanism of immune regulator in eradicating HP infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 80 patients with confirmed HP infection admitted to The Sixth Hospital of Ningbo and The Second Hospital of Yinzhou District of Ningbo from September 2024 to December 2024 were assigned into the control and observation groups were assigned into the control and observation groups (40 cases per group) according to the random number table method. The control group was treated with pantoprazole, citric acid bismuth potassium, amoxicillin capsules, and furazolidone; the observation group received spleen aminopeptide oral lyophilized powder in addition to the control group\u2019s treatment. The duration was 14 days for both groups. Compare the eradication rate, adverse reaction incidence, and changes in immune function between 2 different curative schemes for treatment of HP infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The eradication rate was significantly higher in the observation group than in controls (intention-to-treat: 95.00% vs 80.00%, odds ratio: 0.211, 95% confidence interval: 0.042\u20131.063; per-protocol: 97.44% vs 84.21%, odds ratio: 0.140, 95% confidence interval: 0.016\u20131.228; both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). The incidence of adverse events in the observation group was markedly lower than that in control subjects (7.7% vs 26.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). After treatment, the levels of CD4\n                      <jats:sup>+<\/jats:sup>\n                      , CD3\n                      <jats:sup>+<\/jats:sup>\n                      , and CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      ratio increased in both groups, while the level of CD8\n                      <jats:sup>+<\/jats:sup>\n                      decreased. The levels of CD4\n                      <jats:sup>+<\/jats:sup>\n                      , CD3\n                      <jats:sup>+<\/jats:sup>\n                      , and CD4\n                      <jats:sup>+<\/jats:sup>\n                      \/CD8\n                      <jats:sup>+<\/jats:sup>\n                      in the observation group were significantly higher and the level of CD8\n                      <jats:sup>+<\/jats:sup>\n                      was significantly lower than those in controls (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combination of spleen aminopeptide and bismuth quadruple therapy has a high eradication rate, fewer adverse events, and better immune function improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044911","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:04:53Z","timestamp":1762211093000},"page":"e44911","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of the immunomodulator spleen aminopeptide combined with bismuth in the treatment of Helicobacter pylori infection: A randomized controlled trial"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4384-5754","authenticated-orcid":false,"given":"Wane","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The Sixth Hospital of Ningbo, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Xianxiang Branch, The Second Hospital of Yinzhou District, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Hospital of Ningbo, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Xin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Hospital of Ningbo, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Sixth Hospital of Ningbo, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Affiliated Hospital of Nantong University, Nantong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/gutjnl-2021-325630","article-title":"Chinese consensus report on family-based Helicobacter pylori infection control and management (2021 Edition).","volume":"71","author":"Ding","year":"2022","journal-title":"Gut"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12876-022-02368-w","article-title":"Endoscopic features of oxyntic gland adenoma and gastric adenocarcinoma of the fundic gland type differ between patients with and without Helicobacter pylori infection: a retrospective observational study.","volume":"22","author":"Iwamuro","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12876-023-03100-y","article-title":"Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.","volume":"23","author":"Oh","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/09564624231179505","article-title":"The frequency and duration of side effects associated with the use of oral metronidazole; a prospective study of VITA trial participants.","volume":"34","author":"Ayinde","year":"2023","journal-title":"Int J STD AIDS"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"102208","DOI":"10.1016\/j.coi.2022.102208","article-title":"Beyond the gastric epithelium \u2013 the paradox of Helicobacter pylori-induced immune responses.","volume":"76","author":"Neuper","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"R6-20260915","first-page":"1690","article-title":"An analysis of spleen aminopeptide oral lyophilized powder in the treatment of children after tonsillectomy.","volume":"31","author":"Shen","year":"2017","journal-title":"J Clin Otorhinolaryngol Head Neck Surg"},{"key":"R7-20260915","first-page":"644","article-title":"Process of splenic aminopeptide oral freeze-dried powder on patients with immune dysfunction.","volume":"19","author":"Hua","year":"2019","journal-title":"Eval Anal Drug Use Hosp China"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"e12945","DOI":"10.1111\/hel.12945","article-title":"Transmission routes and patterns of helicobacter pylori.","volume":"28","author":"Duan","year":"2023","journal-title":"Helicobacter"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00284-017-1256-4","article-title":"Role of flagella in the pathogenesis of helicobacter pylori.","volume":"74","author":"Gu","year":"2017","journal-title":"Curr Microbiol"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrmicro3016","article-title":"Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori.","volume":"11","author":"Salama","year":"2013","journal-title":"Nat Rev Microbiol"},{"key":"R11-20260915","first-page":"137","article-title":"Differential inflammatory response to Helicobacter pylori infection: etiology and clinical outcomes.","volume":"8","author":"White","year":"2015","journal-title":"J Inflamm Res"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"8810620","DOI":"10.1155\/2021\/8810620","article-title":"Association of Helicobacter pylori infection and host cytokine gene polymorphism with gastric cancer.","volume":"2021","author":"Zeyaullah","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/IAI.71.6.3496-3502.2003","article-title":"Helicobacter pylori activates toll-like receptor 4 expression in gastrointestinal epithelial cells.","volume":"71","author":"Su","year":"2003","journal-title":"Infect Immun"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"981328","DOI":"10.1155\/2015\/981328","article-title":"Helicobacter pylori and T helper cells: mechanisms of immune escape and tolerance.","volume":"2015","author":"Larussa","year":"2015","journal-title":"J Immunol Res"},{"key":"R15-20260915","first-page":"229","article-title":"Helicobacter pylori deregulates T and B cell signaling to trigger immune evasion.","volume":"421","author":"Reyes","year":"2019","journal-title":"Curr Top Microbiol Immunol"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/pathogens10091099","article-title":"Helicobacter pylori-induced inflammation: possible factors modulating the risk of gastric cancer.","volume":"10","author":"Kumar","year":"2021","journal-title":"Pathogens"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1017\/erm.2017.4","article-title":"Helicobacter pylori as an oncogenic pathogen, revisited.","volume":"19","author":"Graham","year":"2017","journal-title":"Expert Rev Mol Med"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fmicb.2018.00005","article-title":"Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression.","volume":"9","author":"D\u00edaz","year":"2018","journal-title":"Front Microbiol"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcmgh.2016.12.001","article-title":"The clinical evidence linking helicobacter pylori to gastric cancer.","volume":"3","author":"Moss","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1016\/S2468-2667(21)00164-X","article-title":"The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study.","volume":"6","author":"Ling","year":"2021","journal-title":"Lancet Public Health"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"e12714","DOI":"10.1111\/hel.12714","article-title":"The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis.","volume":"25","author":"Zou","year":"2020","journal-title":"Helicobacter"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H pylori antibiotic resistance: prevalence, importance, and advances in testing.","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3748\/wjg.v10.i9.1306","article-title":"Helicobacter pylori L-form and patients with chronic gastritis.","volume":"10","author":"Wang","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1033063","DOI":"10.3389\/fimmu.2022.1033063","article-title":"Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: a multicenter randomized double-blind placebo-controlled trial.","volume":"13","author":"He","year":"2022","journal-title":"Front Immunol"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"e70046","DOI":"10.1002\/jgh3.70046","article-title":"Efficacy of Pyloshot in combination with standard four-drug antimicrobial treatment for Helicobacter pylori eradication: a randomized clinical trial.","volume":"8","author":"Azad","year":"2024","journal-title":"JGH Open"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejps.2017.05.030","article-title":"Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids.","volume":"105","author":"Kang","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2567.2003.01637.x","article-title":"Peptide-based analysis of the amino acid sequence important to the immunoregulatory function of Trypanosoma cruzi Tc52 virulence factor.","volume":"109","author":"Borges","year":"2003","journal-title":"Immunology"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/1061186X.2010.511227","article-title":"Binding patterns of peptide-containing liposomes in liver and spleen of developing mice: comparison with heparan sulfate immunoreactivity.","volume":"19","author":"Tsai","year":"2011","journal-title":"J Drug Target"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/CAD.0000000000001109","article-title":"Safety and efficacy of spleen aminopeptide oral lyophilized powder for improving quality of life and immune response in patients with advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled clinical trial.","volume":"32","author":"Wang","year":"2021","journal-title":"Anticancer Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:03:07Z","timestamp":1789498987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":29,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044911","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-07-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}